STOCK TITAN

Ginkgo Bioworks Holdings Inc Stock Price, News & Analysis

DNA NYSE

Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.

Ginkgo Bioworks Holdings Inc (NYSE: DNA) operates at the forefront of synthetic biology, combining cell programming expertise with biosecurity solutions for industries ranging from pharmaceuticals to agriculture. This news hub provides investors and industry professionals with essential updates on the company's strategic initiatives and technological advancements.

Access real-time announcements including earnings reports, R&D breakthroughs, and strategic partnerships that demonstrate Ginkgo's leadership in biological engineering. The platform serves as a comprehensive resource for tracking developments in their core Cell Engineering services and Biosecurity programs.

Discover updates on Ginkgo's AI-driven innovations, government contracts, and cross-industry collaborations that shape the future of synthetic biology. Content is curated to help stakeholders understand how biological engineering advancements translate to commercial opportunities.

Bookmark this page for streamlined access to verified financial disclosures, operational milestones, and analysis of emerging trends in cell programming technology. Regular updates ensure you stay informed about developments impacting DNA's market position and sector leadership.

Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) has signed a definitive agreement to acquire Bayer's 175,000-square-foot Biologics R&D center for approximately $83 million. This acquisition aims to enhance Ginkgo's agricultural biologicals capabilities. The deal is expected to close in Q4 2022, pending regulatory approvals. Additionally, Ginkgo will enter a three-year collaboration with Bayer, focusing on advancing various agricultural biological programs, including nitrogen fixation. This partnership is anticipated to generate royalty earnings from products developed under the collaboration, potentially offsetting operational costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
-
Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) announced a new cell programming project in collaboration with Sumitomo Chemical Co., Ltd. This partnership focuses on producing sustainable, animal-free molecules for the personal care and cosmetic industries. Leveraging Ginkgo's expertise and extensive codebase, the project aims to enhance sustainability while offering competitive advantages in the market. Sumitomo Chemical recognizes the potential of synthetic biology in meeting the growing demand for eco-friendly products. This initiative complements their ongoing collaboration, initiated in 2021, aimed at bio-based production across multiple sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
none
Rhea-AI Summary

Cronos Group (NASDAQ: CRON) and Ginkgo Bioworks (NYSE: DNA) have achieved a productivity milestone in their collaboration to produce cultured cannabinoids, specifically tetrahydrocannabivarin (THCV). This development is part of an initiative launched in 2018 aimed at creating rare cannabinoids at industrial scale. Cronos has issued approximately 2.2 million common shares to Ginkgo as a result of this achievement. The partnership underscores both companies' commitment to innovation in the cannabis industry, enhancing Cronos' product pipeline with potential market introductions for THCV.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
none
-
Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) will participate in Goldman Sachs' 43rd Annual Global Healthcare Conference on June 15, 2022, at 10:40 a.m. PT. The company focuses on cell programming, providing a platform for biotechnology applications across various sectors including pharmaceuticals and agriculture. Ginkgo has also supported COVID-19 efforts such as pooled testing and vaccine optimization. Further details, including a webcast link, will be available on their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.6%
Tags
none
-
Rhea-AI Summary

On June 7, 2022, Ginkgo Bioworks (NYSE: DNA) announced a collaboration with Novo Nordisk to develop novel expression hosts for pharmaceutical products targeting chronic diseases like diabetes and obesity. This partnership aims to enhance the discovery and development of biological medicines. Ginkgo will receive an upfront R&D fee and may earn milestone payments throughout the collaboration. This multi-year project underscores Ginkgo's commitment to leveraging synthetic biology for improved healthcare solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
none
Rhea-AI Summary

On June 6, 2022, Ginkgo Bioworks (NYSE: DNA) announced the acquisition of assets from Bitome, a leader in real-time metabolite monitoring technology. This technology uses machine learning to enhance bioprocess optimization by providing continuous monitoring of cell culture media. The integration aims to streamline the development timelines of Ginkgo's cell programming platform, potentially accelerating product readiness. Ginkgo's co-founder highlighted that this acquisition will significantly improve strain testing at scale, addressing a critical bottleneck in synthetic biology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
-
Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) will participate in William Blair's 42nd Annual Growth Stock Conference on June 9, 2022, at 11:20 a.m. CT. The conference aims to showcase growth stocks to investors and provide insights into Ginkgo's cell programming platform, which serves various markets from agriculture to pharmaceuticals. Details about the event, including a webcast link and a replay, can be found on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
none
-
Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) and First Serv have announced a non-binding MOU to develop biosecurity capabilities in Qatar, aiming to establish a global pathogen monitoring network. This partnership leverages Ginkgo's biosecurity platform and Qatar's investments in biotechnology to enhance pathogen detection and response capabilities. The initiative is intended to position Doha as a critical node for global pathogen monitoring, facilitating informed public health decisions amid potential biological threats. This collaboration marks Ginkgo's strategic international expansion in biosecurity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.31%
Tags
none
Rhea-AI Summary

Ginkgo Bioworks reported Q1 2022 revenue of $168 million, up 282% YoY, primarily driven by its biosecurity business, which generated $147 million. The company added 11 new Cell Programs, reflecting 175% growth. Full-year revenue guidance has increased from $325-$340 million to $375-$390 million. Ginkgo maintains a $1.5 billion cash balance, supporting future growth initiatives. However, it experienced a significant loss of $(675 million) in operations due to stock-based compensation. The company anticipates adding 60 new Cell Programs in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.76%
Tags

FAQ

What is the current stock price of Ginkgo Bioworks Holdings (DNA)?

The current stock price of Ginkgo Bioworks Holdings (DNA) is $11.07 as of September 17, 2025.

What is the market cap of Ginkgo Bioworks Holdings (DNA)?

The market cap of Ginkgo Bioworks Holdings (DNA) is approximately 629.3M.
Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Stock Data

629.29M
55.40M
6.73%
79.11%
11.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON